Dr Melvin L.K. Chua is a Clinician-Scientist, and Principal Investigator of the Precision Radiation Oncology Programme, Division of Radiation Oncology. He is supported by the National Medical Research Council Clinician-Scientist Award. Dr Chua’s research is focused on precision medicine using prognostic and predictive biomarkers for experimental therapeutics in the management of prostate and nasopharyngeal cancers. He is an active trialist, and is the lead PI for several Phase II and III clinical trials in nasopharyngeal cancer. Dr. Chua serves on several editorial boards, notably as Editor-in-Chief, Annals of Nasopharynx Cancer; and he is the Associate Senior Editor for the Head and Neck Cancer Section of the Red Journal – the official journal for the American Society of Radiation Oncology. He is an active member on the ASCO International working groups, including serving on the International Education Steering Group and the ASCO Asia Pacific Regional Council, and is affiliated with ASCO, AACR, ASTRO, ESMO and ESTRO. Dr. Chua has spoken at over 100 scientific symposiums, and has published over 80 peer-reviewed papers, including high-impact articles in the New England Journal of Medicine, The Lancet, Nature, Cell, and Journal of Clinical Oncology.

Disclosures: